The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers

Pascale A. Cohen; Pascale A. Cohen; Olivier Loudig; Christina Liu; Joseph Albanese; Susan Fineberg

doi:10.3389/fphar.2019.00524

Frontiers in Pharmacology (May 2019)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers

Pascale A. Cohen,
Pascale A. Cohen,
Olivier Loudig,
Christina Liu,
Joseph Albanese,
Susan Fineberg

Affiliations

Pascale A. Cohen: Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
Pascale A. Cohen: Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, United States
Olivier Loudig: Center for Discovery and Innovation, Hackensack University Medical Center (HUMC), Nutley, NJ, United States
Christina Liu: Center for Discovery and Innovation, Hackensack University Medical Center (HUMC), Nutley, NJ, United States
Joseph Albanese: Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States
Susan Fineberg: Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States

DOI: https://doi.org/10.3389/fphar.2019.00524
Journal volume & issue: Vol. 10

Abstract

Read online

We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX® Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX® Recurrence Score.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords